CD59 and cancer: Similarly, increased CD59 expression has been shown to be associated with reduced survival in CRC patients (23), and with reduced overall survival and progression-free survival in patients with prostate adenocarcinoma and diffuse large B cell lymphoma (24, 25) These studies indicate that complements can be used as biomarkers to assess cancer diagnosis and prognosis and have potential application value in tumor immune regulation.